What is the evidence for using hemostatic agents in surgery?

  • Brian L. Erstad


The pharmacological methods used to achieve systemic hemostasis have generated much discussion due to concerns of serious adverse effects (e.g., thromboembolic complications) and costs of therapy in addition to efficacy considerations. There are a limited number of well-controlled trials involving pharmacological hemostasis for spine surgery. In the largest doubleblinded randomized controlled trial to date involving spine surgery, there was a trend toward reduced homologous transfusion in patients receiving aprotinin, but the only statistically significant result (p<0.001) was a reduction in autologous red cell donations. The findings of this trial are important, since the investigators used a number of restrictive transfusion strategies (e.g., autologous donation, low hematocrit trigger for transfusion, blood-salvaging procedures with the exception of no cell saver) that were not always employed in earlier trials involving hemostatic agents. Smaller studies involving antifibrinolytic agents other than aprotinin have demonstrated reductions in blood loss and transfusion requirements in patients undergoing spine surgery, although the results were not always statistically significant. A very large randomized trial would be required to address comparative medication- and transfusion-related adverse events; such a trial involving patients undergoing cardiac surgery is currently being performed. Additionally, cost-effectiveness analyses are needed to help define the role of these agents based on the data that is available.


Hemostatics Antifibrinolytic agents Hemorrhage 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Auvinen O, Baer GA, Nordback I, Saaristo J (1987) Antifibrinolytic therapy for prevention of hemorrhage during surgery of the thyroid gland. Klin Wochenschr 65:253–255CrossRefPubMedGoogle Scholar
  2. 2.
    Benoni G, Fredin H. (1996) Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty. J Bone Joint Surg (Br) 78-B:434–440Google Scholar
  3. 3.
    Bennett-Guerrero E, Sorohan JG, Gurevich ML, Kazanjian PE, Levy RR, Barberá AV, et al (1997) Cost-benefit and efficacy of aprotinin compared with ε-aminocaproic acid in patients having repeated cardiac operations: A randomized blinded clinical trial. Anesthesiology 87:1373–1380CrossRefPubMedGoogle Scholar
  4. 4.
    Bennett-Guerrero E, Spillane WEF, White WD, Muhlbaier LH, Gall SA, Smith PK, et al (1999) Epsilonaminocaproic acid adminstration and stroke following coronary artery bypass graft surgery. Ann Thorac Surg 67:1283–1287CrossRefPubMedGoogle Scholar
  5. 5.
    Berenholz SM, Pronovost PJ, Mullany D, Garrett E, Ness PM, Dorman T, Klag MJ (2002) Predictors of transfusion for spinal surgery in Maryland, 1997 to 2000. Transfusion 42:183–189CrossRefPubMedGoogle Scholar
  6. 6.
    Cha CW, Deible C, Muzzonigro T, Lopez-Plaza I, Vogt M, Kang JD (2002) Allogeneic transfusion requirements after autologous donations in posterior lumbar surgeries. Spine 27: 99–104Google Scholar
  7. 7.
    Dalmau A, Sabate A, Acosta F, Garcia-Huete L, Koo M, Sansano T, et al (2000) Tranexamic acid reduces red cell transfusion better than ε-aminocaproic acid or placebo in liver transplantation. Anesth Analg 91:29–34CrossRefPubMedGoogle Scholar
  8. 8.
    Dietrich W, Späth P, Zühlsdorf M, Dalichau H, Kirchhoff PG, Kuppe H, et al (2001) Anaphylactic reactions to aprotinin reexposure in cardiac surgery. Anesthesiology 95:64–71CrossRefPubMedGoogle Scholar
  9. 9.
    Erstad BL (2001) Antifibrinolytic agents and desmopressin as hemostatic agents in cardiac surgery. Ann Pharmacother 35:1075–1084CrossRefPubMedGoogle Scholar
  10. 10.
    Florentino-Pineda I, Blakemore LC, Thompson GH, Poe-Kochert C, Adler P, Tripi P (2001) The effect of ε-aminocaproic acid on perioperative blood loss in patients with idiopathic scoliosis undergoing posterior spinal fusion. Spine 26:1147–1151CrossRefPubMedGoogle Scholar
  11. 11.
    Garcia-Huete L, Domenech P, Sabate A, MartÍnez-Brotons F, Jaurrieta E, Figueras J (1997) The prophylactic effect of aprotinin on intraoperative bleeding in liver transplantation: A randomized clinical study. Hepatology 26:1143–1148PubMedGoogle Scholar
  12. 12.
    Hedlund PO (1969) Antifibrinolytic therapy with Cyklokapron in connection with prostatectomy. Scand J Urol Nephrol 3:177–182PubMedGoogle Scholar
  13. 13.
    Henry DA, Moxey AJ, Carless PA, O’Connell D, McClelland B, Henderson KM, et al (2003) Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database of Systematic Reviews, 3Google Scholar
  14. 14.
    Hiippala ST, Strid LJ, Wennerstrand MI, Arvela VV, Niemela HM, Mantyla SK, et al (1997) Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. Anesth Analg 84:839–844CrossRefPubMedGoogle Scholar
  15. 15.
    Jeserschek R, Clar H, Aigner C, Rehak P, Primus B, Windhager R (2003) Reduction of blood loss using high-dose aprotinin in major orthopaedic surgery. J Bone Joint Surg (Br) 85-B:174–177CrossRefGoogle Scholar
  16. 16.
    Karnezis TA., Stulberg SD, Wixson RL, Reilly P (1994) The hemostatic effects of desmopressin on patients who had total joint arthroplasty. J Bone Joint Surg 76A(10):1545–1550Google Scholar
  17. 17.
    Kovesi T, Royston D (2003) Pharmacological approaches to reducing allogeneic blood exposure. Vos Sanguinis 84:2–10CrossRefGoogle Scholar
  18. 18.
    Lawrence ACK, Ward-McQuad JN (1996) The effect of epsilon aminocaproic acid on the blood loss after retropubic prostatectomy. Br J Urol 38:308–310Google Scholar
  19. 19.
    Lelorier J, Gregoire G, Benhaddad A, LaPierrre J, Derderian F (1997) Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 337:535–542CrossRefPubMedGoogle Scholar
  20. 20.
    Lentschener C, Benhamou D, Mercier FJ, Boyer-Neumann C, Naveau S, Smadja C, et al (1997) Aprotinin reduced blood loss in patients undergoing elective liver resection. Anesth Analg 84:875–881CrossRefPubMedGoogle Scholar
  21. 21.
    Lentschener C, Cottin P, Bouaziz H, Mercier FJ, Wolf M, Aljabi Y, et al (1999) Reduction of blood loss and transfusion requirement by aprotinin in posterior lumbar spine fusion. Anesth Analg 89:590–597CrossRefPubMedGoogle Scholar
  22. 22.
    Levy JH, Pifarre R, Schaff HV, Horrow JC, Albus R, Spiess B, et al (1995) A multicenter, double-blind, placebocontrolled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 82:2236–2244Google Scholar
  23. 23.
    Miller RA, May MW, Hendry WF, Whitfield HN, Wickham JEA (1980) The prevention of secondary haemorrhage after prostatectomy: the value of antifibrinolytic therapy. Br J Urol 52: 26–28PubMedGoogle Scholar
  24. 24.
    Murkin JM, Haig GM, Beer KJ, Cicutti N, McCutchen J, Comunale ME, et al (2000) Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement. J Bone Joint Surg 82-A(5):675–684Google Scholar
  25. 25.
    Naeye RL (1962) Thrombotic state after a hemorrhagic diathesis, a possible complication of therapy with epsilonaminocaproic acid. Blood 19:694–701PubMedGoogle Scholar
  26. 26.
    Neilipovitz DT, Murto K, Hall L, Barrowman NJ, Splinter WM (2001) A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesth Analg 93:82–87CrossRefPubMedGoogle Scholar
  27. 27.
    Nuttall GA, Horlocker TT, Santrach PJ, Oliver WC, Dekutoski MB, Bryant S (2000) Predictors of blood transfusions in spinal instrumentation and fusion surgery. Spine 25:596–601CrossRefPubMedGoogle Scholar
  28. 28.
    Porte RJ, Molenaar IQ, Begliomini B, Groenland THN, Januszkiewicz A, Lindgren L, et al (2000) Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. Lancet 355:1303–1309CrossRefPubMedGoogle Scholar
  29. 29.
    Press release: $4 million nationwide study aims to prevent life-threatening blood loss in heart surgery patients. Canadian Institutes of Health Research., pp 1–4. cited Feb 3, 2004Google Scholar
  30. 30.
    Samama CM, Langeron O, Rosencher N, Capdevila X, Rouche P, Pegoix M, et al (2002) Aprotinin versus placebo in major orthopedic surgery: a randomized, double-blinded, dose-ranging study. Anesth Analg 95:287–293CrossRefPubMedGoogle Scholar
  31. 31.
    Schött U, Sollén C, Axelsson K, Rugarn P, Allvin I (1995) Desmopressin acetate does not reduce blood loss during total hip replacement in patients receiving dextran. Acta Anaesth Scand 39:592–598PubMedGoogle Scholar
  32. 32.
    Schünemann HJ, Best D, Vist G, Oxman AD, for the GRADED Working Group (2003) Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ 169:677–680PubMedGoogle Scholar
  33. 33.
    Smith RB, Riach P, Kaufman JJ (1984) Epsilon aminocaproic acid and the control of post-prostatectomy bleeding: a prospective double-blind study. J Urology 131:1093–1095Google Scholar
  34. 34.
    Upshur REG (2003) Are all evidencebased practices alike? Problems in the ranking of evidence. CMAJ 169:672–673PubMedGoogle Scholar
  35. 35.
    Urban MK, Beckman J, Gordon M, Urquhart B, Boachie-Adjei O (2001) The efficacy of antifibrinolytics in the reduction of blood loss during complex adult reconstructive spine surgery. Spine 26:1152–1157CrossRefPubMedGoogle Scholar
  36. 36.
    Vinnicombe J, Shuttleworth KED (1966) Aminocaproic acid in the control of haemorrhage after prostatectomy. Lancet 1:230–232CrossRefPubMedGoogle Scholar
  37. 37.
    Wymenga LFA, Van Der Boon, WJV (1998) Obstruction of the renal pelvis due to an insoluble blood clot after epsilon-aminocaproic acid therapy: resolution with intraureteral streptokinase instillations. J Urol 159:490–492PubMedGoogle Scholar
  38. 38.
    Zheng F, Cammisa FP, Sandhu HS, Girardi FP, Khan SN (2002) Factors predicting hospital stay, operative time, blood loss, and transfusion in patients undergoing revision posterior lumbar spine decompression, fusion, and segmental instrumentation. Spine 27:818–824CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Brian L. Erstad
    • 1
  1. 1.Department of Pharmacy Practice and ScienceCollege of PharmacyTucsonUSA

Personalised recommendations